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PYRIDOXINE-DEPENDENT EPILEPSY INITIALLY 
RESPONSIVE TO PHENOBARBITAL
Jaime Lin1, Katia Lin2, Marcelo Rodrigues Masruha3, Luiz Celso Pereira Vilanova4
ABSTRACT - Pyridoxine-dependent epilepsy is a rare autossomal recessive disorder characterized by recur-
rent seizures that are not controlled by anticonvulsant medications but remits after administration of pyr-
idoxine. We report on a 30 day-old girl who presented with seizures during the first day of life, initially re-
sponsive to anticonvulsant therapy, which remitted within two weeks. Seizures were characterized as mul-
tifocal myoclonic jerks of upper and lower limbs associated with buccal-lingual oral movements and eye-
lid blinking. Laboratory and neuroimaging studies were normal. Electroencephalographic record demon-
strated a abnormal background activity with high-voltage epileptic discharges and a burst-suppression pat-
tern. The seizures ceased after oral administration of pyridoxine, but recurred after withdrawal, confirm-
ing the diagnosis. 
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Epilepsia por dependência de piridoxina inicialmente responsiva ao fenobarbital
RESUMO - A epilepsia por dependência de piridoxina é uma doença autossômica recessiva rara caracteriza-
da por crises recorrentes refratárias a tratamento medicamentoso, mas que remitem após a administração 
de piridoxina. Relatamos o caso de menina de 30 dias de vida que iniciou crises convulsivas desde o primei-
ro dia de vida, inicialmente responsivas a tratamento com drogas anticonvulsivantes, mas que reiniciaram 
após a segunda semana de vida. As crises eram caracterizadas por movimentos clônicos erráticos de mem-
bros superiores e inferiores associados a movimentos oromandibulares e piscamentos. Exames laborato-
riais e de neuroimagem foram normais. O exame eletrencefalográfico evidenciou atividade de base desor-
ganizada com descargas epilépticas de alta voltagem associadas a um padrão de surto-supressão. As crises 
cessaram após a administração de piridoxina e recorreram após a sua retirada, confirmando o diagnóstico.
PALAVRAS-CHAVE: piridoxina, epilepsia, manifestações neurológicas.
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Pyridoxine dependency epilepsy (PDE), fi rst recog-
nized in 19541, is a recessively inherited condition in 
which a child has epileptic seizures that are only con-
trolled when pharmacological doses of pyridoxine are 
administered2-4. It is a rare condition, with few epide-
miological studies available revealing a prevalence of 
one case in 687000 births in the United Kingdom5. In 
a more recent study in the Netherlands, a prevalence 
of one case in 396000 births was found6. This rarity 
limits the development of clinical trials that would 
facilitate its diagnosis or determine its optimal treat-
ment regimen7. Atypical presentations include late-
onset PDE (after 19 months of life), seizures that ini-
tially respond to very small doses of pyridoxine but 
then require higher doses8 and epileptic conditions 
that initially respond to anticonvulsants but then re-
spond only to pyridoxine, challenging the diagno-
sis7.
Herein, we present on a defi nite case of PDE in a 
one month-old patient who was initially responsive 
to phenobarbital.
CASE
A 1 month-old girl was admitted to our hospital due to 
frequent seizures. She was born at term, from consanguin-
eous parents (the parents were fi rst degree cousins). Preg-
nancy was uneventful, and her mother did not use any med-
ication, neither prescribed nor over-the-counter, or vitamin 
supplementation. Apgar scores were 9 and 9 after 1 and 5 
minutes. Thirteen hours after birth, seizures were observed, 
being characterized by erratic myoclonic jerks of the upper 
and lower limbs associated with tonic horizontal deviation 
of the eyes to the right. The seizures lasted two minutes 
with spontaneous remission. Two hours later seizures re-
curred and 20 mg/kg phenobarbital was administered intra-
venously. Urine, blood and cerebrospinal fl uid were collect-
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ed for metabolic analysis with normal results. The seizures 
persisted with gradually decreasing frequency and, after ten 
days, the patient was discharged with prescription of 5 mg/
kg/day of phenobarbital. No further seizures were observed 
for the next 15 days and at the day 26 the patient present-
ed persistent episodes of seizures. At 29 days of life, the pa-
tient was admitted to our hospital for investigation. Phys-
ical and neurological examination of the infant revealed 
absence of grasp refl ex, global hipotonia and hyperactivi-
ty of patellar refl exes with clonus at the feet. The seizures 
were characterized by myoclonic movements of upper and 
lower limbs, mainly on the left side of the body associated 
with tonic horizontal deviation of the eyes, eyelid blinking 
and oral movements. Each episode lasted for about 3 min-
utes with a high frequency during the day. Computed to-
mography (CT) scan and magnetic resonance imaging (MRI) 
of the brain were normal as well as complete blood count, 
serum biochemistry, urinalysis and cerebrospinal fl uid anal-
ysis. Electroencephalogram (EEG) revealed an irregular and 
discontinuous background activity with high-voltage spikes 
and a burst-supression pattern (Fig 1A). Also, one electro-
clinical seizure consisting of multifocal myoclonic jerks of 
upper and lower limbs lateralized to the left, with tonic eye 
and head deviation to the right, eyelid blinking and oro-
mandibular movements, associated with lateralized high-
voltage electrographic seizure activity (Fig 1B).
While the diagnostic procedures were performed, a 
therapeutic trial with pyridoxine at 50 mg/day was admin-
istered orally due to her clinical history of seizures starting 
at fi rst day of life without any apparent cause. Approxi-
mately 12 hours after the oral administration of pyridoxine 
the seizures ceased and the patient became seizure free for 
a week. At the end of the fi rst week, the patient stopped 
the medication with recurrence of seizures ten hours later. 
Then, pyridoxine was restarted orally with remission of sei-
zures, and the patient remained seizure free with improve-
ment of the EEG pattern (Fig 2).
One week after seizure control with oral administration 
of pyridoxine, phenobarbital was gradually removed and 
the patient was discharged from the hospital. The patient is 
currently seizure-free after six month of follow-up receiving 
pyridoxine at a dose of 200 mg per day as a single therapy, 
and her last EEG resulted without abnormalities.
The Ethics Committee of the hospital approved the 
study and informed consent was obtained from the par-
ents.
 Fig 1. (A) Sleep EEG with burst-suppres-
sion pattern. (B) High-voltage eletrograph-
ic seizure activity consisting of spike and 
polyspike-wave complexes lateralized to 
the right cerebral hemisphere.
Sensibility = 10 μV, time constant = 0.1 s, 
high frequency fi lter = 35 Hz 
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DISCUSSION
The typical clinical presentation of PDE consists 
of epileptic seizures beginning in the fi rst few days 
of life (usually the first 24 to 48 hours), which are 
totally unresponsive to any conventional drug treat-
ment. Once pyridoxine is administered they cease 
completely2-4,7. Several seizure types may occur and 
usually become increasingly frequent and severe un-
til pyridoxine is started. In retrospect, mothers of af-
fected infants may report episodes of unusual rhyth-
mic intrauterine movements. Although intrauterine 
seizures are very uncommon, this is one of the few 
disorders in which they may occur2-4,7. Other features 
may be present: some babies with early-onset seizures 
also develop encephalopathy, vomiting and breath-
ing diffi culties.
Atypical cases, however, have been reported such 
as late-onset PDE starting after 19 months of life, sei-
zures that initially respond to very small doses of pyri-
doxine but then later require pharmacological doses8 
and epileptic conditions that initially respond to anti-
convulsants but after a certain period of time respond 
only to pyridoxine, challenging its diagnosis9.
In this case, seizures started in the fi rst hours of 
life, with myoclonic jerks of the limbs initialy respon-
sive to usual doses of phenobarbital leading to a de-
lay in the diagnosis.
PDE may be categorized in defi nite cases, defi ned 
as neonates, infants or young children with recurrent 
(two or more) seizures of any type that cease within 
seven days of the administration of oral pyridoxine or 
within 30 minutes of intravenous pyridoxine, that re-
cur when pyridoxine supplementation is withdrawn, 
and than cease again when pyridoxine is restarted; 
and in possible cases, defi ned as above but without 
an attempt to withdrawn pyridoxine. Any recurrence 
of seizures while receiving pyridoxine constitutes an 
exclusion criterion, unless the recurrence occurs dur-
ing a febrile illness5.
In our patient, the pyridoxine dependency was de-
fi ned after an abrupt interruption in the administra-
tion of pyridoxine with recurrence of the seizures and 
its improvement after the reintroduction of pyridoxine.
Subsidiary exams such as brain imaging reveals a 
variety of abnormalities. Some neonatal-onset PDE 
ultrasound scans demonstrates apparent cysts adja-
cent to the lateral ventricles in the brain (similar cysts 
are seen in some metabolic conditions such as organic 
acidemias). The most typical structural abnormality 
identifi ed by CT and/or MRI scans is hypoplasia of the 
posterior part of the corpus callosum and cerebellar 
hypoplasia5. None of these abnormalities were found 
in our patient.
Electroencephalographic fi ndings can be, as well, 
very heterogeneous, with abnormal background ac-
tivity, no sleep organization, discontinuous EEG with 
suppression burst-like pattern and spike and polyspike 
foci9. In our patient, EEG showed a discontinuous sup-
pression burst-like pattern which disappeared after a 
therapeutic trial with pyridoxine.
Based on the seizure’s fast response to pyridox-
ine administration, a diagnostic test using continuous 
EEG recording was developed. According to this test, 
patients with PDE would present an immediate im-
provement of the EEG pattern after the endovenous 
administration of pyridoxine9. The dose of pyridox-
Fig 2. After treatment, sleep EEG with re-
mission of the burst-suppression pattern. 
Sensibility = 10 μV, time constant = 0.1 s, 
high frequency fi lter = 35 Hz 
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ine required in this test is not well established and 
there are reports of testing doses of pyridoxine that 
resulted not only in cessation of clinical seizures but 
also in prolonged depression of neurological and re-
spiratory functions9.
In our patient, endovenous administration pyri-
doxine diagnostic test was not performed since its in-
travenous formulation was not available at that time.
The underlying pathophysiology of this condition 
remains unknown, pyridoxine dependent seizures 
seem to be caused by the defi ciency of cerebral gam-
ma-aminobutyric acid (GABA), a major inhibitory neu-
rotransmitter of the central nervous system. Pyridoxal 
phosphate, the active metabolite of pyridoxine, is the 
coenzyme of glutamate decarboxylase, the rate-lim-
iting enzyme for the production of GABA from glu-
tamate9. However laboratory and genetic studies are 
still inconclusive7.
Although complementary exams can aid in its di-
agnosis, there is not any specifi c test for this condi-
tion. The only way to confi rm its diagnosis is through 
a formal trial of withdrawal. The other certainty in 
this disorder is that pyridoxine has to be continued 
for life1-5,8,9.
The maintenance treatment dose varies widely 
from 2 to 300 mg/day with a daily dose of 200 mg orally 
being mostly recommended. No toxicity or side effects 
were noticed with this dosage1-5,8,9. It is also recom-
mended that pregnant women who previously gave 
birth to a child with PDE should receive 50-100 mg/
day of pyridoxine during the fi nal half of gestation3.
Due to its rarity and in the absence of specifi c bio-
chemical tests the diagnosis of PDE is not always easy. 
This entity is an obligatory differential diagnosis in 
any children (younger than three years old) with early 
onset intractable seizures or status epilepticus, since 
there is a possibility of treatment, which may affect 
its outcome.
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